scholarly journals IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection

2011 ◽  
Vol 12 (4) ◽  
pp. 300-309 ◽  
Author(s):  
J-Y Chen ◽  
C-Y Lin ◽  
C-M Wang ◽  
Y-T Lin ◽  
S-N Kuo ◽  
...  
Keyword(s):  
Sustained Virological Response ◽  
Virological Response ◽  
Genetic Variations ◽  
Hcv Infection ◽  
Interferon Α ◽  
Chronic Hcv Infection ◽  
Chronic Hcv ◽  
High Sustained Virological Response

Impact of sustained virological response to chronic hepatitic C antiviral therapy on new onset diabetes mellitus type 2 after controlling for metabolic syndrome

2017 ◽  
Vol 65 (4) ◽  
pp. 765-771 ◽  
Author(s):  
Prashant Pandya ◽  
Chaitanya Pant ◽  
Ryan Taylor ◽  
Olurinde Oni
Keyword(s):  
Diabetes Mellitus ◽  
Metabolic Syndrome ◽  
Sustained Virological Response ◽  
Virological Response ◽  
Hcv Infection ◽  
History Of ◽  
Chronic Hcv Infection ◽  
Chronic Hcv ◽  
New Onset

The high cost associated with antiviral treatment for chronic hepatitis C virus (HCV) infection mandates further investigation in the context of preventing complications such as type 2 diabetes mellitus (DM2). We determined the cumulative incidence of DM2 in subjects with chronic HCV infection who received concomitant pegylated interferon (Peg-IFN) and ribavirin. We conducted a retrospective analysis of data obtained from Veterans Administrations Informatics and Computing Infrastructure (VINCI) to identify an adult cohort of patients without diabetes with chronic HCV infection who received Peg-IFN-based therapy between October 2001 and December 2011. Patients with history of HIV, hepatitis B infection, hepatocellular cancer (HCC), non-HCC cancers, and history of transplantation were excluded. Sustained virological response (SVR) was defined as negative HCV RNA 3 months after completion of therapy. Using Cox proportional hazards regression for multivariable analysis, we determined that patients who achieved SVR were at a significantly less risk of developing DM2. Adjusted survival rates showed that the responders' group was significantly less likely to develop DM2 over time (HR 0.60, CI 0.48 to 0.74, p<0.001). Peg-IFN-based therapy in chronic HCV patients that resulted in SVR significantly decreased the risk of developing DM2 and independently predicts the development of new onset disease after controlling for correlates of metabolic syndrome.

Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting

2011 ◽  
Vol 16 (6) ◽  
pp. 815-824 ◽  
Author(s):  
Thomas Reiberger ◽  
Martin Obermeier ◽  
Berit A Payer ◽  
Axel Baumgarten ◽  
Lutwin Weitner ◽  
...  
Keyword(s):  
Sustained Virological Response ◽  
Virological Response ◽  
Real Life ◽  
Response Rates ◽  
Hcv Infection ◽  
Hiv Patients ◽  
Real Life Setting ◽  
Chronic Hcv Infection ◽  
Chronic Hcv

Immunotherapy with interferon-α-induced dendritic cells for chronic HCV infection (the results of pilot clinical trial)

2017 ◽  
Vol 66 (1) ◽  
pp. 31-43 ◽  
Author(s):  
Elena Chernykh ◽  
Olga Leplina ◽  
Ekaterina Oleynik ◽  
Marina Tikhonova ◽  
Tamara Tyrinova ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Dendritic Cells ◽  
Hcv Infection ◽  
Interferon Α ◽  
Chronic Hcv Infection ◽  
Chronic Hcv

scholarly journals Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon α-2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype

2015 ◽  
Vol 9 (2) ◽  
pp. 215-220 ◽  
Author(s):  
Tatsuo Kanda ◽  
Masato Nakamura ◽  
Reina Sasaki ◽  
Shin Yasui ◽  
Shingo Nakamoto ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Adverse Events ◽  
Sustained Virological Response ◽  
Virological Response ◽  
Hcv Infection ◽  
Direct Acting Antivirals ◽  
Chronic Hcv ◽  
Direct Acting ◽  
Peginterferon Α

Direct-acting antivirals with or without peginterferon α (PEG-IFN α) plus ribavirin are now available for the treatment of hepatitis C virus (HCV) infection. Direct-acting antivirals are potent inhibitors of HCV replication, but some of them occasionally possess serious adverse events. We experienced a 64-year-old female with chronic HCV genotype 1b infection who showed elevated alanine aminotransferase of 528 IU/l at week 9 after the commencement of treatment of simeprevir with PEG-IFN α-2a plus ribavirin. However, she achieved sustained virological response at week 24 after the end of treatment. In Japan, we also have to treat elderly patients infected with HCV and/or advanced hepatic fibrosis. Until an effective interferon-free regimen is established, direct-acting antivirals with PEG-IFN plus ribavirin may still play a role in the treatment for certain patients. To avoid serious results from adverse events, careful attention and follow-up will be needed in the treatment course of simeprevir with PEG-IFN plus ribavirin for chronic HCV infection.

scholarly journals New Therapies for Hepatitis C Virus

PRILOZI ◽  
2015 ◽  
Vol 36 (2) ◽  
pp. 119-132
Author(s):  
Hari Polenakovik
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Etiologic Agent ◽  
Hcv Infection ◽  
Interferon Α ◽  
Risk Of Death ◽  
Duration Of Therapy ◽  
Chronic Hcv Infection ◽  
Chronic Hcv

Abstract Hepatitis C virus (HCV), the major etiologic agent of "non-A, non-B hepatitis" was discovered 26 years ago. Even before its discovery, interferon-α (IFN) was already being used for treatment of this infection. The next two decades saw a series of incremental improvements of the IFN therapies by extending the duration of therapy, using IFN in combination with oral ribavirin, using pegylated IFN with ribavirin, and most recently adding oral compounds that inhibit the HCV replication (directly acting antivirals - DAAs) to that regimen. DAAs target multiple steps in the HCV life cycle and are now used in combination to treat HCV infection without the need of IFN. These IFN-free, oral DAAs regimens are highly efficacious, have minimal toxicity and are given for short duration. Approved DAAs can cure more then 90% of persons with chronic HCV infection, thereby reducing the risk of death from cirrhosis and hepatocellular carcinoma. However, these drugs are very expensive, and currently their exorbitant cost significantly restricts the access to this therapy for many HCV infected patients.

Sign in / Sign up

Export Citation Format

Share Document